Orsini James A, Haddock Marie, Stine Lynne, Sullivan Eileen K, Rabuffo Tara S, Smith Gary
New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, USA.
J Am Vet Med Assoc. 2003 Aug 1;223(3):336-9. doi: 10.2460/javma.2003.223.336.
To determine the odds of moderate or severe gastric ulceration in racehorses treated with various antiulcer medications.
Unmatched case-control study.
798 horses in active race training (252 Thoroughbreds and 546 Standardbreds). Only horses that had been receiving a single antiulcer medication or no antiulcer medication for at least 2 weeks prior to examination were included.
Gastroscopy was performed on each horse by a single individual who was not aware of the horses' antiulcer treatments, and severity of gastric ulceration was scored. Signalment and medication history were recorded. Logistic regression was used to determine whether identification of moderate or severe ulceration was associated with treatment, age, breed, or sex. Treatments were grouped as no treatment, buffer, sucralfate, histamine type 2 receptor antagonist, compounded omeprazole, proprietary omeprazole at a low dosage, and proprietary omeprazole at a high dosage.
Only proprietary omeprazole was associated with significantly lower odds of moderate or severe ulceration, compared with no treatment. Risks of moderate or severe gastric ulceration in horses receiving a buffer, sucralfate, a histamine type 2 receptor antagonist, or compounded omeprazole were not significantly different from risks in horses receiving no antiulcer medication.
Results suggest that the proprietary formulation of omeprazole was associated with a significantly lower risk of moderate or severe gastric ulceration, compared with no treatment, in racehorses in active race training, whereas other antiulcer medications were not.
确定接受各种抗溃疡药物治疗的赛马发生中度或重度胃溃疡的几率。
非匹配病例对照研究。
798匹正在进行积极赛马训练的马匹（252匹纯种马和546匹标准bred马）。仅纳入在检查前至少2周内接受单一抗溃疡药物治疗或未接受抗溃疡药物治疗的马匹。
由一名不了解马匹抗溃疡治疗情况的个体对每匹马进行胃镜检查，并对胃溃疡的严重程度进行评分。记录马匹的特征和用药史。采用逻辑回归分析来确定中度或重度溃疡的识别是否与治疗、年龄、品种或性别有关。治疗分为未治疗、缓冲剂、硫糖铝、组胺2型受体拮抗剂、复方奥美拉唑、低剂量专利奥美拉唑和高剂量专利奥美拉唑。
与未治疗相比，只有专利奥美拉唑与中度或重度溃疡的几率显著降低有关。接受缓冲剂、硫糖铝、组胺2型受体拮抗剂或复方奥美拉唑治疗的马匹发生中度或重度胃溃疡的风险与未接受抗溃疡药物治疗的马匹相比无显著差异。
结果表明，在正在进行积极赛马训练的赛马中，与未治疗相比，专利剂型的奥美拉唑与中度或重度胃溃疡的风险显著降低有关，而其他抗溃疡药物则不然。
